China Tongfu (01763) announced its 2023 results, with revenue of about 6.635 billion yuan, an increase of 7.8 billion yuan over the previous year...
According to the Zhitong Finance App, China Tongpu (01763) announced its 2023 results, with revenue of about 6.635 billion yuan, up 7.82% year on year; gross profit fell 1% year on year to 3.482 billion yuan, profit attributable to the company's equity shareholders was about 371 million yuan, a decrease of 5.43% year on year; profit per share was 1.16 yuan, with a recommended final dividend of 31.31 points per share.
Among them, pharmaceuticals achieved operating revenue of 4.129 billion yuan, an increase of 5.2% over the previous year. Among them, revenue from radiopharmaceuticals for imaging diagnosis and treatment was 1,683 billion yuan, up 15.3% year on year; revenue from breath testing was 2,324 billion yuan, down 1.0% year on year.
The decrease in gross profit was mainly due to lower gross margin of radiation therapy equipment and related services and other business segments, which had a large increase in revenue, which reduced the overall gross profit increase.